Your cholesterol numbers came back “normal” — but if heart disease runs in your family, there is one number your doctor almost certainly never ordered. Lipoprotein(a), or Lp(a) (pronounced “L-P-little-a”), is the most common inherited cardiovascular risk factor in existence, and most people have no idea they carry it. This guide tells you exactly what to test, when to test it, how to read the result, and what to do next.
If you have watched a parent or sibling have a heart attack at 55 with “decent” cholesterol, or if you have had a cardiac event yourself despite doing everything right, there is a real chance Lp(a) is part of the answer. The test costs less than a dinner out. It requires no fasting. And the result you get back is the same number it has been since you were born — which is both the problem and the point.
What Is Lp(a) and Why Does It Matter More Than Most Cholesterol Markers
The difference between LDL cholesterol and Lp(a) — why one responds to lifestyle, the other does not
Think of Lp(a) as a faulty delivery truck. Your body uses LDL particles to deliver cholesterol where it is needed. Lp(a) is a modified version of that truck with a broken brake system and a sticky coating — it is far more likely to embed itself in artery walls and trigger the chain reaction of damage (what researchers call atherosclerosis, or plaque buildup inside artery walls) that eventually causes a heart attack or stroke. Unlike your standard LDL truck, which you can slow down with diet, exercise, or statins, the number of these faulty Lp(a) trucks on the road is almost entirely determined at birth by the genes you inherited. Lp(a) concentration is controlled to a major extent by genetics — specifically by copy number variation in the LPA gene — meaning it is largely fixed from birth and not meaningfully altered by diet or exercise. You cannot reduce the fleet size through lifestyle. But knowing how many you have changes every other decision you make about your heart.
Elevated Lp(a) is a genetically transmitted, co-dominant trait — meaning it acts as an independent risk driver for cardiovascular disease regardless of your other cholesterol numbers. Your LDL could be textbook perfect. Your triglycerides could be low. Your HDL could be excellent. And Lp(a) could still be quietly loading the dice against you.
How elevated Lp(a) drives plaque buildup in arteries and calcific aortic valve disease
Elevated Lp(a) is described in the clinical literature as the most prevalent inherited cholesterol disorder and is a causal risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease — a condition where calcium deposits accumulate on the heart’s aortic valve, progressively narrowing it until the heart can no longer pump blood efficiently. This is not a secondary association. Lp(a) does not merely travel alongside heart disease risk — it contributes directly to the biological mechanisms driving it. The sticky protein coating on Lp(a) particles — called apolipoprotein(a) — makes them far more prone to infiltrating artery walls and initiating the inflammatory response that drives plaque formation.
Why your standard cholesterol panel almost certainly missed it
Despite the profound impact of elevated Lp(a) on cardiovascular risk, Lp(a) testing remains absent from most routine lipid panels globally. Your standard lipid panel measures total cholesterol, LDL, HDL, and triglycerides. Lp(a) is an entirely separate particle that requires a separate test — and most guidelines have been slow to mandate it. The evidence base for Lp(a) has outpaced clinical implementation, which is a polite way of saying that the science has been clear for years and the healthcare system has not caught up. This is the kind of gap that a routine annual check-up was not designed to close — not because doctors don’t care, but because population-level screening protocols were never built to account for individually inherited risk factors sitting outside the standard panel.
Who Should Get Tested — The Priority List
Family history of early heart disease, stroke, or heart attack before age 60
Early cardiovascular events in a first-degree relative — a parent, sibling, or child — are the single clearest signal that something inherited may be at work. If your father had a heart attack at 52 or your mother had a stroke at 58, Lp(a) should already have been on someone’s radar. It almost certainly was not. Get the test.
Personal history of ASCVD with no obvious cause (normal LDL, non-smoker, healthy weight)
ASCVD (atherosclerotic cardiovascular disease — plaque-related events including heart attacks, strokes, and angina) in someone who “shouldn’t” have it is a classic Lp(a) presentation. If you have already had a cardiac event and your doctors have never found a convincing explanation, this is the test you may have been missing. Identifying elevated Lp(a) can meaningfully guide risk reclassification and intensify preventive treatment decisions — it changes what your doctor should recommend, not just flag a risk.
First-degree relatives of anyone already confirmed to have elevated Lp(a)
Because the trait is inherited in a co-dominant pattern, siblings and children of someone with confirmed high Lp(a) face a substantial probability of carrying it themselves. Cascade testing of relatives of confirmed high-Lp(a) individuals is recommended in the clinical literature — meaning if anyone in your immediate family has been told their Lp(a) is elevated, that result is medically relevant to you too, even if you feel completely well.
Anyone reassessing cardiovascular risk who has only ever had a standard lipid panel
If you are in your 40s or 50s, you are doing all the right things — exercising, watching your diet, getting your annual bloods — but you have never had an Lp(a) test, you have an incomplete picture. Current evidence supports targeted testing of high-risk groups, with identification of those most likely to benefit being essential for optimising cardiovascular risk assessment. For anyone with a family history, that means you.
When to Test and How Often
Why once in a lifetime is the general recommendation — and when repeat testing may be warranted
Because Lp(a) is genetically determined, it stays remarkably stable throughout your life. Unlike LDL, which fluctuates with diet, weight, and medication, your Lp(a) level at 45 is essentially the same number it was at 25 and will be at 65. This means that for most people, a single measurement is sufficient — you are not checking for change, you are establishing a baseline fact about your biology. Repeat testing may be warranted if there are significant changes in your clinical picture — such as a new cardiovascular diagnosis, pregnancy (which can temporarily alter levels), or when considering hormone replacement therapy.
Optimal age to test for primary prevention versus after a cardiac event
For primary prevention (testing before any cardiovascular event occurs), the ideal window is your 30s to mid-40s — early enough that the result can meaningfully shape a decade or more of prevention strategy, but mature enough that you and your doctor can act on it with the full context of your other risk factors. After a cardiac event, Lp(a) testing should happen as part of a full workup, particularly if the event was unexplained by conventional risk factors.
Should children be tested if a parent has high Lp(a)?
This question is no longer theoretical. Expert panels on cardiovascular health in children and adolescents have recommended measuring Lp(a) as part of paediatric lipid screening — recognising that this is not exclusively an adult risk factor. If a parent has confirmed elevated Lp(a), testing a child in their early teens gives the family decades of lead time to build the most protective cardiovascular environment possible around an elevated baseline risk.
How to Get the Test in Singapore
What to ask your GP or cardiologist — exact wording to use
The test will not appear automatically on a standard blood panel. You need to ask for it by name. The phrase that works: “I’d like to add an Lp(a) test to my next blood draw — it’s not on the standard lipid panel but I understand it’s available as a separate add-on, and I have a family history of early heart disease.” Most GPs and all cardiologists will be familiar with the test. Some GPs may need to refer you to a specialist or a private lab.
Private lab options and typical cost range [NEEDS VERIFICATION for Singapore-specific pricing]
In Singapore, Lp(a) testing is available through major private laboratories including Parkway Laboratory Services, Healthway Medical, and specialist cardiology clinics at private hospitals such as Mount Elizabeth and Gleneagles. Typical costs are in the range of SGD 30–80 for the test alone, though pricing varies by provider and whether it is ordered alongside a full lipid panel. These figures should be verified directly with the lab or clinic before you book, as pricing changes. Importantly, the test requires no fasting — you can walk in on any given morning without preparation.
Understanding the units: nmol/L versus mg/dL and why it matters for your result
This is where many people get confused — and where errors happen. Lp(a) is reported in two different units depending on the laboratory: nmol/L (nanomoles per litre) and mg/dL (milligrams per decilitre). These are not interchangeable, and the thresholds that define “high” differ between them. A result of 125 nmol/L and a result of 50 mg/dL both represent the same general risk threshold — the accepted cut-off in most major cardiology guidelines — but the numbers look very different on a lab report. Always check which unit your lab used before comparing your result to any reference range you find online.
How to Read Your Result
What the numbers mean — low, borderline, high, very high thresholds
Below 75 nmol/L (approximately 30 mg/dL) is generally considered low risk. The range between 75 and 125 nmol/L (roughly 30–50 mg/dL) is borderline — clinically relevant in the context of other risk factors. Above 125 nmol/L (50 mg/dL) is widely recognised as the threshold for elevated Lp(a) requiring active management of all modifiable cardiovascular risk factors. Above 175 nmol/L (approximately 70 mg/dL) is considered very high, associated with substantially increased risk of early cardiovascular events. These thresholds reflect current major cardiology society guidelines, though exact cut-offs vary slightly between European and American frameworks.
Why the same number can mean different things depending on your other risk factors
A result of 130 nmol/L in a 45-year-old non-smoker with optimal blood pressure, no family history of early heart disease, and well-controlled LDL carries a different clinical weight than the same number in someone with hypertension, a parent who died of a heart attack at 58, and an LDL that has never been aggressively managed. Lp(a) is an independent risk driver — it raises your risk regardless of other factors — but the absolute magnitude of that risk is always calculated in the context of your full cardiovascular profile. This is the conversation to have with a cardiologist, not a data point to interpret in isolation.
The important caveat: assay standardisation is still an unsolved problem
Here is something most lab reports do not tell you: there is currently no universally standardised assay for measuring Lp(a). Different laboratories use different testing methods, which means a result from one lab may not be directly comparable to a result from another. This is why nmol/L is increasingly preferred over mg/dL — it reflects a particle count rather than a mass measurement, and is less affected by the size variation in Lp(a) particles between individuals. If you are retesting after a period of time, try to use the same laboratory and the same unit so that any comparison is at least internally consistent.
What to Do When Your Result Comes Back High
Risk reclassification — what changes in your prevention strategy
A high Lp(a) result does not mean a heart attack is inevitable. What it does mean is that your risk category may need to be revised upward — and that revision should change what happens next. Identifying elevated Lp(a) can reclassify a person from moderate to high cardiovascular risk and prompt earlier or more intensive preventive treatment. In practical terms, this may mean more aggressive LDL targets, earlier initiation of statins, closer blood pressure monitoring, and more frequent cardiovascular imaging to track subclinical plaque development.
Lifestyle still matters: aggressive LDL lowering, blood pressure control, and avoiding smoking
You cannot move your Lp(a) number with diet or exercise. That is a genetic fact. But that is not a reason to accept elevated risk passively — it is a reason to be more aggressive about every risk factor you can move. Smoking is particularly dangerous in the context of elevated Lp(a) and should be eliminated completely. LDL should be driven as low as your cardiologist is willing to target. Blood pressure should be kept in the optimal range, not merely the “acceptable” range. The logic is straightforward: if one variable in your cardiovascular risk equation is fixed at a high value, you have more reason than average to minimise every other variable you control.
Emerging therapies specifically targeting Lp(a) — what is in the pipeline
For the first time, there are therapies in late-stage clinical trials designed specifically to reduce Lp(a) levels — not as a side effect, but as their primary mechanism. RNA-based therapies (drugs that work by silencing the genetic instructions that produce Lp(a)) including pelacarsen and olpasiran have shown reductions of 70–90% in Lp(a) levels in trials. These are not yet approved or available as standard care, but outcomes data from large trials is expected within the next few years. If you have elevated Lp(a) today, the therapeutic landscape in 2027 or 2028 may look meaningfully different.
Cascade testing — who in your family should know your result
Cascade testing of family members is recommended when one relative has elevated Lp(a), because the trait is inherited and siblings and children face a meaningful probability of also carrying it. A high Lp(a) result is not just information about you. Your siblings carry the same parental genes. Your children inherited half of yours. Sharing your result — and specifically recommending they request the test — is one of the most genuinely useful things you can do with this information. It costs them nothing more than asking a question at their next blood draw.
What to Ask Your Doctor — A Conversation Starter Script
Many people leave this kind of appointment having absorbed a lot but asked nothing. Here are the specific questions worth bringing to your GP or cardiologist after reading this guide.
- “Can you add an Lp(a) test to my next blood panel? I understand it’s not on the standard lipid panel — I’d like to request it specifically.”
- “My [parent/sibling] had a heart attack at [age]. Does that change my cardiovascular risk category in your assessment?”
- “If my Lp(a) comes back above 125 nmol/L, does that change my LDL target or the threshold at which you’d recommend medication?”
- “Should I be having any imaging — a coronary calcium score or carotid ultrasound — to look for subclinical plaque given my family history?”
- “If I have elevated Lp(a), should my children or siblings be tested?”
These are not aggressive questions. They are exactly the kind of questions a well-informed patient should be asking — and any cardiologist worth their time will welcome them.
At your next GP or cardiology appointment, ask specifically: “Can you add an Lp(a) test to my next blood panel?” — and mention your family history of heart disease. If your result comes back above 125 nmol/L (or 50 mg/dL, depending on the unit your lab uses), ask your doctor directly whether this changes your cardiovascular risk category and whether your current prevention strategy — LDL targets, blood pressure management, and aspirin use — should be revisited in light of it.
